Related Experiment Video
Updated: Aug 26, 2026
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Based on Raman spectroscopy and clinical laboratory tests: Developing a fusion model to predict neoadjuvant therapy
Xueyi Chen1, Zhenlong Li2, Yanjun Li3
1Department of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of medicine, University of Electronic Science and Technology of China, Chengdu, China; Department of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Background:
Neoadjuvant therapy (NAT) constitutes a pivotal component of comprehensive breast cancer treatment. Early prediction of NAT efficacy is crucial for personalised treatment and improving patient prognosis. However, effective early prediction methods remain lacking at present.
Methods:
A retrospective cohort study was conducted involving 406 patients with invasive breast cancer. Baseline clinical laboratory parameters and serum Raman spectra were collected. Key features were selected using an attention mechanism to construct a multimodal fusion prediction model based on Transformers. The model was trained and its predictive efficacy evaluated.
Results:
The mean age was 50.88 years. Overall, 134 women achieved pCR following NAT. The fusion model outperformed single-modality approaches in predicting pCR, achieving the highest AUC (0.790) and accuracy (0.752). This performance significantly surpassed single-modality models based solely on clinical laboratory tests (AUC = 0.759) or Raman spectroscopy (AUC = 0.669). Key predictive features identified include lipase, Ki-67 index, HER2 status, HFR%, and albumin.
Conclusion:
Multimodal fusion of Raman spectroscopy with clinical laboratory indicators effectively enhances the predictive performance of NAT efficacy, providing a non-invasive, dynamic adjunctive decision-making tool for personalised breast cancer treatment.
